Iceplex C. Difficile Assay Kit, Iceplex System
C. Difficile Toxin Gene Amplification Assay. 510(k) K132726, from Primeradx (Mansfield, MA). Product code OZN, class 2.
As of Nov 21, 2026, K132726 is an FDA 510(k) held by Primeradx, substantially equivalent on Nov 29, 2013 after 91 days, with no recalls tied to it in FDA's recall database.
- Review time: 91 days
- Recalls: 0
The PrimeraDx ICEPlex® C. difficile Assay is for the qualitative detection of the Clostridium difficile toxin B gene (tcdB gene) in nucleic acids purified from unpreserved liquid or soft human stool specimens from patients suspected of having C. difficile infection (CDI). The ICEPlex C.
- BD Max Cdiff Assay, BD Max InstrumentK130470 · Geneohm Sciences Canada, Inc. (Bd Diagnostics) · Apr 2, 2013
- cobas® Cdiff Nucleic acid test for use on the cobas® Liat® System (07454945190); cobas® Cdiff Positive and Negative…K260045 · Roche Molecular Systems, Inc. · Aug 28, 2026
- Xpert C. difficile/EpiK243730 · Cepheid® · Feb 28, 2025
- Great Basin Toxigenic C. difficile Direct Test (CDF2)K232092 · Vela Operations USA · Nov 14, 2023
- cobas Cdiff nucleic acid test for use on the cobas Liat SystemK212427 · Roche Molecular Systems, Inc. · Oct 20, 2021
- cobas Cdiff nucleic acid test for use on the cobas Liat SystemK210385 · Roche Molecular Systems, Inc. · Sep 9, 2021
- Document
- 510(k) summary (PDF) ↗
- Type
- Traditional
- Received
- Aug 30, 2013
- Review panel
- Microbiology
- Regulation
- 21 CFR 866.3130
One page per 510(k), De Novo and original PMA. Recalls are those FDA's recall database ties to this number; recalls of related devices that cite another number are not shown. Refreshed weekly. Predicates are read by Arca from the text of FDA's 510(k) summary PDFs, most of them scans: a device number counts when the summary names it as a predicate or as the device it is substantially equivalent to. About 97% of those read were right on a sample we checked by hand; summaries from before 2000 often name predicates without a number, so older devices show fewer. Pivotal studies are read by a model from FDA's De Novo decision summaries and PMA SSEDs; a count or result is shown only when its numbers appear in FDA's text. openFDA device 510(k), PMA and recall files